Reduced brain atrophy rates are associated with lower risk of disability progression in patients with relapsing multiple sclerosis treated with cladribine tablets

BACKGROUND: Neuroimaging studies have used magnetic resonance imaging-derived methods to assess brain volume loss in multiple sclerosis (MS) as a reliable measure of diffuse tissue damage. METHODS: In the CLARITY study (ClinicalTrials.gov NCT00213135), the effect of 2 years’ treatment with cladribin...

Popoln opis

Shranjeno v:
Bibliografske podrobnosti
izdano v:Mult Scler
Main Authors: De Stefano, Nicola, Giorgio, Antonio, Battaglini, Marco, De Leucio, Alessandro, Hicking, Christine, Dangond, Fernando, Giovannoni, Gavin, Sormani, Maria Pia
Format: Artigo
Jezik:Inglês
Izdano: SAGE Publications 2017
Teme:
Short Reports
Online dostop:https://ncbi.nlm.nih.gov/pmc/articles/PMC5818021/
https://ncbi.nlm.nih.gov/pubmed/28140753
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1177/1352458517690269
Oznake: Označite
Brez oznak, prvi označite!

Podobne knjige/članki